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Abstract
Background: Immunological markers (CD4 count) are used in developing countries to decide on initiation of
antiretroviral therapy and monitor HIV/AIDS disease progression. HIV is an incurable chronic illness, making quality
of life paramount. The direct relationship between quality of life and CD4 count is unclear. The purpose of this
study is to determine the relationship between change in CD4 count and quality of life measures in a Ugandan
cohort of people living with HIV.
Methods: We prospectively assessed quality of life among 1274 HIV patients attending an HIV clinic within a
national referral hospital over a period of 6 months. Quality of life was measured using an objective measure, the
Medical Outcomes Study HIV health survey summarized as Physical Health Score and Mental Health Score and a
subjective measure, the Global Person Generated Index. Generalized estimating equations were used to analyze the data.
The primary predictor variable was change in CD4 count, and the outcome was quality of life scores. We controlled for
sociodemographic characteristics, clinical factors and behavioral factors. Twenty in-depth interviews were conducted to
assess patient perception of quality of life and factors influencing quality of life.
Results: Of the 1274 patients enrolled 1159 had CD4 count at baseline and six months and 586 (51 %) received
antiretroviral therapy. There was no association found between change in CD4 count and quality of life scores at
univariate and multivariate analysis among the study participants whether on or not on antiretroviral therapy.
Participants perceived quality of life as happiness and well-being, influenced by economic status, psychosocial
factors, and health status.
Conclusions: Clinicians and policy makers cannot rely on change in immunological markers to predict quality of life in
this era of initiating antiretroviral therapy among relatively healthy patients. In addition to monitoring immunological
markers, socioeconomic and psychosocial factors should be underscored in management of HIV patients.
Background
There is an established relationship between immuno-
logical and virological outcomes as important markers of
HIV disease progression and treatment failure [1, 2].
CD4 cell count has been reported to have a strong asso-
ciation with progression to AIDS-related illness or death
[3]. With the availability of antiretroviral therapy (ART)
coupled with early diagnosis, people living with HIV
(PLHIV) now live longer. Quality of life (QoL) has be-
come an important outcome variable to be monitored,
in addition to other clinical outcomes and biological
markers such as CD4 count [4]. With the prolonged sur-
vival of HIV patients in resource-limited settings, the
focus in HIV care is no longer only on clinical outcomes
such as morbidity and mortality but on QoL as well.
QoL measurement is now more essential than ever, to
optimize patient outcomes [4]. However, it is not clear
how QoL and CD4 count are related, with few studies
and inconsistent results. Understanding the relationship
between immunological response and QoL will improve
the effectiveness, receptiveness and accuracy of care
and other support services to PLHIV in resource-
limited settings.
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Some studies have looked at factors associated with
QoL, including CD4 count in developed and developing
count [5–12]. CD4 count has been associated with QoL
in some studies reporting poor QoL with low CD4
count or high QoL with high CD4 count [6, 8, 11–15].
Baseline CD4 count has been found to be a predictor of
health-related QoL [14]. Another cross-sectional study
reported that improving CD4 count is likely to also im-
prove health-related QoL [15]. More recent studies in
Africa have reported a positive association between
CD4 count and QoL. A multi-site study in Uganda and
Kenya found a positive association between Physical
Health Score (PHS) and CD4 count among a mixed
population of patients on ART and those not on ART
[12] . Related to this, a study in Nigeria found a CD4
count ≥350 cells/μL was associated with better QoL scores
in the physical domain [11]. These studies were not de-
signed to systematically evaluate the relationship between
measured change in CD4 count and any change in QoL.
Most of these studies were cross-sectional and thus could
not provide the temporal association between QoL and
CD4 count.
The studies that have been carried out to specifically
assess the relationship between immunological and viro-
logical outcomes and QoL have reported conflicting out-
comes. For example, in a randomized double-blind
controlled study carried out over a period of 24 months,
an association between change in QoL and change in
CD4 count was reported, and change in CD4 count was
a stronger long-term predictor of QoL compared with
change in viral burden [16]. Another study in South
Africa assessed the change in CD4 count and viral load
among HIV patients not on ART and those that had
been on ART for 12 months and found weak correla-
tions between CD4 count and QoL measures [17]. Simi-
lar weak correlations and no associations were reported
by Venter and colleagues in a cross–sectional study [18].
Bucciardi and colleagues [19] showed no correlation be-
tween CD4 count and health-related QoL among ART-
experienced patients; this was also reported by Magafu
and colleagues among adult Tanzanian patients [20], as
well as Arpinelli and colleagues among Italian patients
[21]. In India, a mixed picture was reported; some QoL
subscales were associated with CD4 count but the ma-
jority of subscales were not; associations were only re-
ported in the subgroup with low CD4 count [22]. A
positive association between CD4 and emotional well-
being was reported in a cohort of men living with HIV
at baseline and at 12 months; however, there was no
such association with any other QoL subscales at base-
line and at 12 months [23]. Interestingly, Call and col-
leagues [24] found an association with CD4 count and
PHS as well as another five out of the eight SF-36 health
survey subscale scores. Patients with higher CD4 counts
had higher QoL scores; however, there was no associ-
ation between CD4 count and MHS in this group.
Very few studies in resource-limited settings have
assessed immunological markers (CD4 count) and QoL
over time, yet immunological markers and QoL change
over time [6]. Additionally, the few studies that have
assessed the association between QoL and CD4 count
worldwide have reported inconsistent results. The aim
of this study was to determine the association between
change in QoL and change in immunological status
(CD4 count) among PLHIV attending an urban clinic
in Uganda. While patients are on ART, the CD4 count
is expected to increase and hence provide better im-
munity and, most likely, better QoL. When a person
with HIV is not on ART, the CD4 count is expected to
decrease with time, and the person would start on ART
when eligible. The assumption is that QoL drops with
decreased CD4 count. Our study will test this assump-
tion and contribute to the knowledge gap in developing
countries, where CD4 count is the immunological
marker most used for determining ART initiation and
HIV/AIDS disease monitoring. The findings from in-
depth interviews will be used to explain the findings
from quantitative analysis.
Methods
Study participants
A cohort of people living with HIV was drawn from a
population of HIV patients attending the HIV clinic at
the Mulago National Referral Hospital. The inclusion
criteria for the study were adult patients ages ≥18 years;
none were on ART at baseline. One group was ready to
initiate therapy and started ART on the day of the
baseline interview (n = 640), and the other group was
not eligible for ART (CD4 >350 cells/μL) and received
basic care and no ART (n = 634). Patients were ex-
cluded if they did not consent or were acutely ill and
required medical or surgical treatment or admission to
the hospital.
Sample size
After a literature search, we could find no studies com-
paring change in CD4 count and change in QoL among
patients on ART and non-ART patients. We used a
longitudinal study in which all patients were on ART
and calculated the sample size for the ART group in
our study.
Mean PHS at baseline was 49.57 (SD 8.14) and the
mean change in PHS per week was 0.09 (SD 0.10). The
change in 24 weeks was postulated at 2.16 and hence
the mean PHS estimated to be 51.73 [16].
We used PASS 13 software (NCSS, LLC, Kaysville,
UT, USA) for sample size calculations. A sample size of
107 achieves 80 % power to detect a difference of −2.2
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between the null hypothesis of mean 49.5 and the alter-
native mean of 51.7. Estimated sample size for one-
sample comparison of mean to hypothesized value: a
sample size of 150 is required to detect a change in PHS
of 2.16 assuming alpha =0.05, power =90 %.
Study design
This was a prospective cohort study. Participants were
enrolled consecutively as they registered per clinic day.
Enrollment began in April 2012 and was completed in
December 2013. World Health Organization (WHO)
guidelines were used to initiate ART in patients with a
CD4 count less than 350, or co-infected with TB re-
gardless of CD4 count, or co-infected with hepatitis B
regardless of CD4 count [25]. We approached 1274
PLHIV and all consented to participate in the study. Of
these, 640 initiated ART on the day of the baseline
interview. Additionally, 20 in-depth interviews were
conducted to understand what this study population
perceived as QoL and what influenced their QoL. The
20 interviewees were a purposely selected subset of the
total 1274 enrolled in the study; they were chosen to
represent differences in age and gender among partici-
pants. In addition, 10 of these 20 participants received
ART, and 10 were not eligible for ART and received
only basic care (no ART). This qualitative study has
been described elsewhere [26]. The figure below illus-
trates the patient recruitment procedure (Fig. 1).
Data collection
At enrollment, we collected data using a questionnaire
and structured interview on sociodemographic character-
istics such as age, gender, marital status, socioeconomic
status (employment status, income per month and level of
education), behavioral characteristics (alcohol consump-
tion (CAGE) and smoking), clinical characteristics (WHO
disease stage, antiretroviral therapy (on ART or not), and
depression (see below for measure details)), and history of
opportunistic infection. Blood was drawn at the baseline
visit for CD4 counts. If a CD4 blood test had been done
within 14 days before the enrollment day, it was not re-
peated and the CD4 count was retrieved from the clinic
records. At 6 months, blood was drawn for another CD4
count and the results given to the patient on their next
clinic visit by their primary care provider. Interviews were
conducted in person by the first author and two super-
vised research assistants at baseline, 3 months and
6 months. To maintain data quality, the first author
reviewed a sample of the data collection forms to en-
sure correctness. Double data entry in Epidata v3.1 was
done by the two assistants and the first author checked
and compared these data with the original scripts if
Fig. 1 Schematic patient flow chart showing the recruitment and follow up of 1274 study participants at the Mulago HIV clinic in Uganda
between April 2012 and December 2013
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there were discrepancies. At the end of the study, we
reviewed the records of patients lost to follow-up to de-
termine if there were any differences in the reasons for
loss between the two groups (ART and non-ART).
Measures
We used two measures to assess QoL so as to capture
the subjective and objective aspects of QoL. The object-
ive measure used was the Medical Outcomes Study HIV
(MOS-HIV) health survey and the subjective measure
was the Global Person Generated Index (GPGI). The ob-
jective measure mainly captures levels of functioning
and symptoms and gives a clinician an indication of how
the patient is progressing. However, this measure ignores
individual patient perception and what may be import-
ant to them regarding their QoL. The subjective meas-
ure allows the individual to express what their QoL is
like [27], thereby providing an understanding of how the
individual perceives their QoL.
The MOS-HIV tool is preferred because it is an HIV
disease-specific measure and among the most widely used
patient-reported outcome measures [28, 29]. It has been
validated in Uganda [7, 30, 31] and found to be useful in
capturing QoL data in this setting. The validated Luganda
version of the MOS-HIV was used in this study. The
MOS-HIV has also been proved to be able to differentiate
between patients on ART and those that are not on ART,
and between symptomatic and asymptomatic HIV pa-
tients [32]. It has 10 subscales: physical function, role
function, social function, cognitive function, mental
health, energy and fatigue, health distress, health percep-
tions, pain and overall QoL [28, 29]. The subscales are
summarized into two summary scores, PHS and MHS,
using a recommended mean of 50 (SD 10) [33].
The GPGI score is a subjective measure that has been
validated in other developing countries [34]. The GPGI
measures global QoL and allows the individual to define
and rate their QoL. The individual will therefore define
“what” QoL is and “how” QoL is for them [27]. The
GPGI is capable of capturing “response shift” [35]. The
individual states five areas of their life that are the most
important to them and these are scored on a scale of 0–
6, where zero is the worst possible you could imagine
and 6 is exactly as you would like to be. Respondents are
then asked to “spend” 10 points to show which areas of
their life they feel are most important to their overall
QoL. In our study, participants were asked to spend
10,000 Uganda shillings, which they could relate to more
easily than 10 points. They did not have to spend their
shillings on all five items but they had to spend all the
shillings. The scores are aggregated and transformed to
a scale of 0–100. A higher score indicates a better global
QoL. A cutoff of 60 was used to determine high global
QoL (≥60) and low global QoL (<60) [36].
The Center for Epidemiological Depression Scale
(CES-D) [37] was used to screen for depression. The
CES-D has been used widely in Uganda [38, 39]. A cut-
off total score of ≥16 is used to indicate probable depres-
sion [37].
The CAGE questionnaire was used to screen for alco-
holism. CAGE has been shown to have cross-cultural
validity because it does not focus on the specifics of al-
cohol use [40]. A cutoff of ≥2 was used to indicate prob-
able alcohol abuse. A score of 2 or 3 represents a high
index of suspicion of alcoholism, and a score of 4 may
be diagnostic for alcoholism [41].
ART adherence was measured using a 3-day self-report
and a cutoff of 95 % was used to determine adherence
(≥95 %) and non-adherence (<95 %). Self-reporting has
been shown to have adherence levels not different from
unannounced pill count, visual analog scale and electronic
drug monitoring [42]. A cutoff of 95 % adherence has also
been associated with better viral suppression [43, 44].
Statistical analysis
The main outcome was QoL using the subscales from
the MOS-HIV as PHS and MHS, and global QoL mea-
sured by the GPGI. The MOS-HIV was scored using the
guidelines obtained from the Mapi Research Trust, and
missing data were handled as per the measurement
guidelines [28, 29, 33]. Descriptive characteristics were
analyzed and presented as percentages, means with
standard deviations, medians, and interquartile ranges.
The CD4 count change was obtained as the difference
between the 6-month and baseline CD4 counts as the
main predictor variable. Univariate analysis was done for
PHS and MHS and CD4 change using linear generalized
estimating equations (GEE) among patients on ART and
those not on ART separately. In a multivariate linear
model, we controlled for baseline CD4, sociodemo-
graphic characteristics, behavioral characteristics, and
other clinical characteristics that have been shown to be
associated with QoL, such as WHO disease stage and
depression (confounders were selected from previous
studies on the basis of clinical, epidemiological and bio-
logical relevance). Depression was not added as a covari-
ate in the MHS models to avoid collinearity because the
MHS partly assesses for depression. Logistic GEE were
used to assess the association between GPGI score and
change in CD4 count in the univariate and multivariate
analyses, controlling for the potential confounders listed
above. The analysis was done separately for patients on
ART and those that did not receive ART. The inter-
action between CD4 change and study visit as a measure
of time was tested for significance. All statistical ana-
lyses were conducted using Stata statistical software
12.1 (StataCorp LP, College Station, TX, USA). Statis-
tical significance was defined as a p-value <0.05. The
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interviews were transcribed and translated for coding
and thematic analysis. Data were analyzed manually
using a framework approach to thematic analysis.
Ethics
The study was approved by Makerere University College
of Health Sciences Higher Degrees Research and Ethics
Committee and the Uganda National Council for Sci-
ence and Technology (UNCST, Ref HS 1161). All partic-
ipants provided written, informed consent prior to
participation in the study. Participants were informed
that refusal to participate would not affect their care ser-
vices in any way. No personal identifiers such as names
were collected. Confidentiality was maintained through-
out the study, from the data collection process to storage
and analysis of the data.
Results
Of the 1274 PLHIV enrolled in the study, 115 (9 %)
were lost to follow-up by the 6-month visit. Of the pa-
tients lost to follow-up, 54 (47 %) were on ART; there
were no differences in the attrition factors (died, lost,
and changed care facility) between patients on ART and
those not on ART. The total used for this analysis was
1159 patients who had both baseline and 6-month CD4
counts. The majority of these were women 823 (71 %),
and 586 (51 %) were on ART. The majority of the pa-
tients were less than 30 years old 482 (41 %). Only 322
(28 %) of the total 1159 participants reported using al-
cohol; 184 (57 %) were probable alcohol abusers with a
CAGE score ≥2. Table 1 has the details of the socio-
demographic characteristics.
The median baseline CD4 count was 396 cells/μL
(IQR 260–634) and 501 at 6 months (IQR 381–635).
Among individuals on ART, 545 (93 %) had an adher-
ence score of ≥95 % at the 3- and 6-month visits. Overall,
313 (27 %) participants had an opportunistic infection at
baseline and 220 (19 %) at 6 months. Details of other clin-
ical characteristics are given in Table 2.
The MOS-HIV subscales used to construct the PHS and
MHS at baseline, month 3 and month 6 ranged from pain
with a mean of 26.4 (SD 23.4) to social functioning with a
mean of 93.0 (SD 18.8), pain 21.2 (18.6) to social function-
ing 96.0 (13.5), pain 20.4 (17.9) to social functioning 96.1
(31.6) at baseline, month 3 and month 6 respectively.
Table 3 has details of all the subscales. These were trans-
formed means to a scale of 0–100 to make easy compari-
sons with other MOS-HIV Survey data.
The baseline mean PHS was 46.6 (SD 4.2), MHS 46.6
(SD 4.2) and median GPGI 71.7 (IQR 56.7–85.0) Table 3.
No statistically significant change in CD4 count over
time was found when testing for interaction among the
three QoL outcomes (PHS p = 0.440, MHS p = 0.245 and
GPGI score OR = 1 p = 0.030) indicating similar patterns
of change over time in both groups. Table 4 summarizes
the PHS, MHS and GPGI scores at all three visits as
means (SD) and medians (IQR).
Table 1 Socio-demographic characteristics of 1159 study
participants at the Mulago HIV clinic in Uganda between April
2012 and December 2013
Characteristic Whole sample ART No ART
n = 1159 (%) n = 586 (%) n = 573 (%)
Gender
Female 823 (71) 386 (66) 436 (76)
Male 336 (29) 200 (34) 137 (24)
Education level
≤ Primary 594 (51) 298 (51) 296 (52)
Secondary 458 (40) 232 (40) 226 (39)
Apprenticeship 83 (7) 42 (7) 41 (7)
Tertiary 24 (2) 14 (2) 10 (2)
Age in years
<30 482 (41) 255 (44) 227 (40)
30–39 426 (37) 212 (36) 214 (37)
≥40 251 (22) 119 (20) 132 (23)
Monthly income (USD)
<20 362 (31) 180 (31) 182 (32)
20–60 329 (29) 154 (26) 175 (30)
>60 468 (40) 252 (43) 216 (38)
Religion
Christian 951 (82) 476 (81) 475 (83)
Muslim 187 (16) 99 (17) 88 (15)
Other 21 (2) 11 (2) 10 (2)
Marital status
Currently married 703 (61) 352 (60) 351 (61)
Divorced/separated 274 (24) 144 (24) 130 (23)
Single 76 (6) 45 (8) 31 (5)
Widowed 106 (9) 45 (8) 61 (11)
Employed
Yes 938 (81) 478 (82) 460 (80)
No 221 (19) 108 (18) 113 (20)
Social support
Yes, family 920 (79) 488 (83) 432 (75)
Yes, other 194 (17) 80 (14) 114 (20)
None 45 (4) 18 (3) 27 (5)
Alcohol consumption
Yes 322 (28) 141 (24) 181 (32)
No 837 (72) 445 (76) 392 (68)
Smoking
Yes 50 (4) 23 (4) 27 (5)
No 1109 (96) 563 (96) 546 (95)
Abbreviation: ART, antiretroviral therapy
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There was no significant association between change
in CD4 count and PHS, MHS and GPGI QoL scores in
the univariate analysis and after adjusting for potential
confounders of PHS and GPGI scores among patients
on ART. Confounders included baseline CD4 count,
study visit, gender, age, education level, marital status,
alcohol consumption, monthly income, smoking status,
diagnosis of depression, social support, presence of op-
portunistic infection, WHO disease stage, religion, and
employment status. For MHS, the potential confounders
were as above, but without the depression screening
score. Change in CD4 count and PHS, MHS and GPGI
after adjusting for potential confounders were not sig-
nificant. Low education level, probable depression and
WHO stage III and IV were associated with low PHS, fe-
males had lower MHS and MHS improved with time
and alcohol consumption and probable depression were
also related to low GPGI. Detailed results are presented
in Table 4. There was no evidence of multicollinearity;
the standard errors (SE) for change in CD4 were the
same in the univariate and multivariate analyses for
PHS, MHS and GPGI score (Table 5).
Among patients not receiving ART, there was no sig-
nificant association between change in CD4 count and
PHS and MHS in the univariate and multivariate ana-
lyses. There was a negative association between GPGI
score and change in CD4 count with OR = 0.9991 in the
univariate analysis, and OR = 0.9990 in the multivariate
analysis for high GPGI with a unit change in CD4. The
associations were very small (0.09 %,) in univariate ana-
lysis and 0.1 %) in multivariate analysis. Older age, prob-
able depression were associated with low PHS, low
income and presence of opportunistic infection were as-
sociated with low MHS and older age, low education
and probable depression were also negatively associated
with GPGI (Table 6).
The in-depth interviews revealed other factors to be
important for a good QoL in addition to good health,
such as having money, building a house, family relations
with spouses and children. The themes identified were
Table 2 Clinical characteristics of 1159 study participants at the
Mulago HIV clinic in Uganda between April 2012 and December
2013
Characteristic Whole sample ART No ART
n = 1159 (%) n = 586 (%) n = 573 (%)
WHO disease stage
Stages I and II 962 (83) 470 (80) 492 (86)
Stages III and IV 197 (17) 116 (20) 81 (14)
Opportunistic infection
Yes 310 (27) 187 (32) 123 (21)
No 849 (73) 399 (68) 450 (79)
Depression screening, baseline score
No depression (<16) 777 (67) 380 (65) 397 (69)
Probable depression (≥16) 382 (33) 206 (35) 176 (31)
Depression screening score, 6 months
No depression (<16) 845 (73) 443 (76) 402 (70)
Probable depression (≥16) 314 (27) 143 (24) 171 (30)
Baseline CD4 count (cells/μL)
<100 104 (9) 104 (18) 0 (0)
101–350 436 (38) 436 (74) 0 (0)
>350 619 (53) 46 (8) 573 (100)
CD4 count at 6 months
<100 27 (2) 26 (4) 1 (0)
101–350 205 (18) 179 (31) 26 (5)
>350 927 (80) 381 (65) 546 (95)
Abbreviation: ART, antiretroviral therapy
Table 3 Summary of the MOS HIV subscales of 1274 study participants used to construct the PHS and MHS at baseline, month
three and month six at the Mulago HIV clinic, 2013
Subscale Range of raw scores Transformed mean
score (SD) at baseline
Transformed mean
score (SD) at Month 3
Transformed mean
score (SD) at Month 6
General Health 5–25 53.4 (13.3) 52.7 (11.8) 53.2 (11.5)
Physical Health 6–18 86.3 (16.8) 89.7 (15.9) 90.3 (15.3)
Role Function 2–4 67.1 (37.5) 72.9 (32.7) 74.0 (31.6)
Social Function 1–6 93.0 (18.8) 96.0 (13.5) 96.1 (13.1)
Cognitive Function 4–24 81.3 (16.9) 86.3 (14.6) 87.2 (14.6)
Pain 2–11 26.5 (23.7) 21.2 (18.6) 20.4 (17.9)
Mental Health 5–30 55.5 (7.9) 54.7 (6.4) 54.3 (6.6)
Vitality 4–24 49.5 (8.2) 48.2 (6.4) 48.2 (6.4)
Health Distress 4–24 86.0 (22.1) 93.1 (15.7) 93.6 (15.6)
Quality of life 1–5 47.4 (26.3) 42.6 (24.1) 40.2 (24.5)
Health Transition 1–5 47.4 (26.3) 42.6 (24.1) 40.2 (24.5)
Abbreviation: SD, standard deviation
Baseline visit there were 1274 patients, month three 1217 and month six 1159 patients and data was collected from April 2012 to December 2013
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“liveabilty of environment (work and finances), Life abil-
ity (health, treatment, stigma, depression), utility of life
(goals/expectations, family relations) and appreciation of
life (happiness) [26]. However, they still suffered from
stigma, depression and lack of disclosure of their HIV
status details of the qualitative results have been pub-
lished elsewhere [26].
Discussion
Our evaluation provides evidence that there is no signifi-
cant association between changes in CD4 count and
changes in PHS, MHS and GPGI QoL scores among pa-
tients on ART and those not on ART. The change in
GPGI score was too small for change in CD4 count to
be considered a predictor of change in QoL [45]. Con-
trary to our expectations, we found no positive associ-
ation between change in CD4 count and QoL among
patients on ART and no expected association between
decreased CD4 count and decreased QoL among pa-
tients not on ART.
The lack of association between CD4 change and QoL
scores is possibly because the majority of the partici-
pants were asymptomatic with relatively high CD4
counts, with only 104 (9 %) of patients with counts less
than 100 cells/ μL at baseline and 27 (2 %) at 6 months.
Therefore, because most participants had a high CD4
count, they had a good QoL. There may be insufficient
change in their CD4 count to make a significant change
in their QoL. In earlier studies [6, 9], ART was initiated
in patients who were quite ill; thus, the change in CD4
count could easily be related to improvement in QoL be-
cause patients went from experiencing severe ill-health to
rapid recovery of health and functioning, which are likely
to impact QoL. Because most of our patients had a high
CD4 count (>200), they were relatively well and any in-
crease in CD4 count may not have translated to better
QoL. Also, the global QoL in this study population was
high in all categories, with IQR between 60 and 85. A score
range of 60–80 on subjective measures has been reported
as normal QoL [36], so there was not much room for
change. The overall mean PHS and MHS in our study are
comparable to what has been recently reported among
Ugandan and Kenyan patients, with mean PHS of 44.9 and
mean MHS of 46.2 [12]. Interestingly, that study reported
a positive association between CD4 count and QoL; how-
ever it was a cross-sectional analysis with a sample size of
1337 participants and no temporal association compared
with our longitudinal study. In addition, their analysis com-
bined patients on ARTand those that were not on ART.
Another possible reason for our results is that QoL is
a subjective construct and there are many other factors
that come into play other than immunological markers.
Patients have goals and expectations for QoL that
change with time, and clinicians cannot assume that an
increase in CD4 count will automatically lead to a better
QoL for patients. Our qualitative data showed that QoL
as well as general well-being were influenced by income,
relationships, emotional well-being and health status
[26]. There may also be a role played by other factors,
such as socioeconomic status and behavioral characteris-
tics. In the multivariate analysis depression was nega-
tively associated with QoL and this has been reported in
other settings [46], Older age has also been associated
with poor QoL similar to what was reported in our study
[47, 48]. Females patients similar to our study findings
have also been reported to have poor QoL compared to
males among Ethiopians [49] and other factors such as
income and level of education have also been reported
to be associated with QoL among PLHIV in both devel-
oped and developing countries [5, 7, 13, 50] comparable
to the findings from our study. QoL is multifaceted and
highly subjective. QoL, response to HIV diagnosis, and
treatment trajectory are not linear processes [51] and
many other factors contribute to the outcome. Studies of
other chronic diseases such as asthma have reported that
patients’ “valued life activities” are more strongly associ-
ated with changes in QoL than traditional clinical and
functional measures [52]. Harding and others also re-
ported that spiritual and social problems affected pa-
tients living with HIV in East Africa rather than physical
challenges [12].
Our finding of weak to no correlation between change
in CD4 count and QoL scores is similar to findings of
Table 4 Summary of QoL scores of study participants at the
three study visits attending the Mulago HIV clinic in Uganda
between April 2012 and December 2013 indicated as mean
(SD) or median (IQR)
Summary measures Whole sample ART NO ART
PHS Mean (SD) Mean (SD) Mean (SD)
Baseline visit 46.6 (4.2) 46.5 (4.5) 46.6 (3.9)
Month 3 visit 46.9 (4.0) 47.0 (3.9) 46.9 (4.0)
Month 6 visit 47.1 (3.8) 47.2 (3.8) 47.0 (3.9)
MHS Mean (SD) Mean (SD) Mean (SD)
Baseline visit 46.9 (4.2) 46.4 (4.5) 47.4 (3.8)
Month 3 visit 47.5 (3.4) 47.3 (3.5) 47.7 (3.4)
Month 6 visit 47.4 (3.4) 47.1 (3.4) 47.6 (3.3)
GPGI Median (IQR) Median (IQR) Median (IQR)
Baseline visit 71.7 (56.7–85.0) 71.6 (55.0–85.0) 73.3 (56.7–86.7)
Month 3 visit 73.3 (56.7–85.0) 71.7 (56.7–85.0) 75.0 (56.7–86.7)
Month 6 visit 73.3 (60.0–85.0) 73.3 (58.3–85.0) 73.3 (60.0–85.0)
Abbreviations: QoL, quality of life; SD, standard deviation; IQR, interquartile
range; PHS, Physical Health Score; MHS, Mental Health Score; GPGI, Global
Person Generated Index
Sample size 1274 at baseline (ART n = 640, no ART n = 634), 1217(ART n = 625,
no ART = 592) at month 3 and 1159 (ART n = 586, no ART n = 576) at month 6,
data collected from April 2012 to December 2013 at the Mulago HIV clinic
in Uganda
Mwesigire et al. Health and Quality of Life Outcomes  (2015) 13:144 Page 7 of 14
Table 5 Comparison of change in CD4 count and QoL among 586 patients receiving ART at the Mulago HIV clinic in Uganda between April 2012 and December 2013
Outcome QoL score PHS MHS GPGI
Predictor variable β coefficient
(95 % CI)/ odds ratio (95 % CI)
Univariate Multivariate Univariate Multivariate Univariate Multivariate
Change in CD4 count 0.0001 (−0.0013 to 0.0016) 0.0001 (−0.0014 to 0.0015) 0.0004 (−0.0009 to 0.0018) 0.0009 (−0.0005 to 0.0023) 0.9999 (0.9990 to 1.0001) 0.9999 (0.9991 to 1.0008)
SE = 0.0007 SE = 0.0007 SE = 0.0007 SE = 0.0007 SE = 0.0004 SE = 0.0004
Baseline CD4 count (cells/μL)
<100 Ref Ref Ref Ref Ref Ref
101−350 0.82 (0.21 to 1.44) 0.64 (0.02 to 1.25) 0.12 (−0.44 to 0.68) −0.02 (−0.61 to 0.57) 0.89 (0.63 to 1.24) 0.79 (0.54 to 1.14)
>350 0.90 (0.03 to 1.76) 0.62 (−0.23 to 1.47) 0.32 (−0.47 to 1.11) 0.26 (−0.56 to 1.08) 0.81 (0.51 to 1.30) 0.68 (0.41 to 1.13)
Gender
Male Ref Ref Ref Ref Ref Ref
Female −0.30 (−0.78 to 0.18) 0.02 (−0.50 to 0.54) −0.87 (−1.30 to −0.43) −0.78 (−1.28 to −0.29) 0.83 (0.64 to 1.07) 1.14 (0.84 to 1.56)
Age in years
<30 Ref Ref Ref Ref Ref Ref
30−39 −0.46 (−0.98 to 0.053) −0.44 (−0.95 to 0.07) 0.46 (−0.01 to 0.93) 0.27 (−0.23 to 0.76) 0.92 (0.70 to 1.20) 0.91 (0.67 to 1.22)
≥40 −0.56 (−1.17 to 0.05) 0.50 (−1.12 to 0.11) 0.15 (−0.40 to 0.71) 0.10 (−0.49 to 0.69) 0.93 (0.67 to 1.30) 0.95 (0.66 to 1.38)
Education level
≤Primary Ref Ref Ref Ref Ref Ref
Secondary 0.69 (0.21 to 1.17) 0.44 (−0.03 to 0.92) −0.19 (−0.63 to 0.25) −0.11 (−0.56 to 0.35) 1.27 (0.98 to 1.65) 1.12 (0.84 to 1.48)
Apprenticeship 1.74 (0.81 to 2.66) 0.96 (0.06 to 1.86) 0.38 (−0.47 to 1.23) 0.23 (−0.63 to 1.09) 1.17 (0.74 to 1.84) 0.84 (0.53 to 1.39)
Tertiary 2.31 (0.94 to 3.68) 1.72 (0.28 to 3.15) −1.05 (−2.31 to 0.21) −1.86 (−3.23 to −0.48) 3.72 (1.17 to 11.87) 3.65 (1.06 to 12.56)
Marital status
Currently married Ref Ref Ref Ref Ref Ref
Divorced/separated −0.15 (−0.70 to 0.40) 0.15 (−0.40 to 0.70) −0.60 (−1.10 to −0.10) −0.42 (−0.95 to 0.10) 0.73 (0.54 to 0.97) 0.73 (0.54 to 0.99)
Single 0.53 (−0.34 to 1.39) 0.58 (−0.31 to 1.46) −0.68 (−1.46 to 0.10) −0.52 (−1.37 to 0.33) 0.92 (0.58 to 1.44) 0.85 (0.51 to 1.42)
Widowed −0.59 (−1.45 to 0.27) −0.41 (−1.27 to 0.46) −0.73 (−1.51 to 0.05) −0.49 (−1.31 to 0.33) 0.63 (0.40 to 0.99) 0.73 (0.45 to 1.18)
Alcohol consumption
Yes Ref Ref Ref Ref Ref Ref
No −0.15 (−0.68 to 0.39) 0.02 (−0.51 to 0.55) −0.20 (−0.69 to 0.28) −0.27 (−0.77 to 0.24) 1.49 (1.13 to 1.96) 1.56 (1.14 to 2.14)
Income per month in USD
<20 Ref Ref Ref Ref Ref Ref
20−60 −0.22 (−0.82 to 0.37) −0.18 (−0.91 to 0.55) −0.12 (−0.67 to 0.43) −0.47 (−1.17 to 0.23) 1.00 (0.73 to 1.37) 0.99 (0.65 to 1.50)
>60 0.77 (0.24 to 1.31) 0.37 (−0.33 to 1.06) 0.27 (−0.23 to 0.76) −0.26 (−0.93 to 0.41) 1.59 (1.20 to 2.12) 1.43 (0.95 to 2.14)
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Table 5 Comparison of change in CD4 count and QoL among 586 patients receiving ART at the Mulago HIV clinic in Uganda between April 2012 and December 2013
(Continued)
Smoking status
Yes Ref Ref Ref Ref Ref Ref
No −0.40 (−1.61 to 0.80) −0.27 (−1.46 to 0.92) 0.43 (−0.66 to 1.52) 0.78 (−0.35 to 1.92) 1.33 (0.73 to 2.42) 1.04 (0.50 to 2.18)
Social support
Yes, family Ref Ref Ref Ref Ref Ref
Yes, other 0.52 (−0.14 to 1.19) 0.49 (−0.15 to 1.14) −0.19 (−0.80 to 0.41) −0.10 (−0.72 to 0.51) 0.83 (0.60 to 1.15) 0.98 (0.69 to 1.39)
None −0.37 (−1.72 to 0.97) −0.44 (−1.76 to 0.87) −1.27 (−2.49 to −0.04) −1.15 (−2.41 to 0.10) 0.74 (0.41 to 1.34) 0.84 (0.44 to 1.63)
Depression score No depression
(<16) Ref Ref - - Ref Ref
Probable depression (≥16) −1.95 (−2.35 to −1.55 −1.71 (−2.12 to −1.31) 0.37 (0.30 to 0.45) 0.39 (0.31 to 0.49)
Opportunistic infection
Yes Ref Ref Ref Ref Ref Ref
No 0.46 (−0.03 to 0.96) 0.07 (−0.42 to 0.56) 0.30 (−0.15 to 0.75) 0.13 (−0.34 to 0.59) 1.33 (1.03 to 1.72) 1.24 (0.94 to 1.64)
WHO stage
Stages I and II Ref Ref Ref Ref Ref Ref
Stages III and IV −1.09 (−1.66 to −0.52) −0.76 (−1.33 to −1.19) −0.34 (−0.86 to 0.19) −0.24 (−0.78 to 0.31) 0.76 (0.57 to 1.02) 0.78 (0.57 to 1.07)
Religion
Christian Ref Ref Ref Ref Ref Ref
Muslim −0.41 (−1.02 to 0.20) −0.17 (−0.77 to 0.43) 0.48 (−0.08 to 1.03) 0.55 (−0.02 to 1.13) 1.10 (0.79 to 1.53) 1.11 (0.78 to 1.59)
Other 0.03 (−1.02 to 0.20) −0.20 (−1.79 to 1.38) −0.70 (−2.21 to 0.81) −0.71 (−2.22 to 0.81) 0.89 (0.41 to 1.90) 0.76 (0.36 to 1.59)
Employment status
Yes Ref Ref Ref Ref Ref Ref
No −0.31 (−0.90 to 0.28) −0.12 (−0.90 to 0.65) −0.27 (−0.81 to 0.26) −0.39 (−1.13 to 0.35) 0.78 (0.58 to 1.05) 0.97 (0.63 to 1.51)
Abbreviations: 95 % CI, 95 % confidence interval; SE, standard error
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Table 6 Comparison of change in CD4 count and QoL among 573 patients not receiving ART at the Mulago HIV clinic in Uganda between April 2012 and December 2013
Outcome QoL score PHS MHS GPGI
Predictor variable
β coefficient/Odds
Ratio (95 % CI)
Univariate Multivariate Univariate Multivariate Univariate Multivariate
Change in CD4 count −0.0003 (−0.0015 to 0.0010) −0.0003 (−0.0011 to 0.0008) −0.0001 (−0.0012 to 0.0009) 0.0000 (−0.0010 to 0.0011) 0.9991 (0.9983 to 0.9998) 0.9990 (0.9982 to 0.9997)
SE = 0.0006 SE = 0.0006 SE = 0.0005 SE = 0.0005 SE = 0.0004 SE = 0.0004
Gender
Male Ref Ref Ref Ref Ref Ref
Female −0.56 (−1.11 to −0.14) −0.71 (−1.33 to −0.09) −0.13 (−0.58 to 0.33) 0.07 (−0.46 to 0.61) 1.13 (0.84 to 1.52) 1.26 (0.89 to 1.77)
Age in years
<30 Ref Ref Ref Ref Ref Ref
30−39 −0.21 (−0.73 to 0.32) −0.32 (−0.86 to 0.22) 0.39 (−0.05 to 0.83) 0.38 (−0.08 to 0.84) 0.78 (0.58 to 1.05) 0.79 (0.58 to 1.09)
≥40 −1.16 (−1.77 to −0.55) −1.35 (−2.00 to −0.70) 0.29 (−0.22 to 0.81) 0.17 (−0.39 to 0.73) 0.62 (0.45 to 0.87) 0.62 (0.43 to 0.89)
Education level
≤Primary Ref Ref Ref Ref Ref Ref
Secondary 0.74 (0.24 to 1.23) 0.66 (0.16 to 1.15) 0.12 (−0.29 to 0.54) 0.11 (−0.02 to 0.53) 1.51 (1.15 to 1.97) 1.26 (0.96 to 1.66)
Apprenticeship 0.96 (0.04 to 1.87) 0.46 (−0.48 to 1.40) −0.03 (−0.80 to 0.73) −0.03 (−0.83 to 0.78) 1.75 (1.03 to 2.98) 1.50 (0.86 to 2.63)
Tertiary 1.33 (−0.59 to 3.25 0.82 (−1.03 to 2.67) −0.11 (−1.73 to 1.50) 0.06 (−1.54 to 1.65) 11.85 (1.73 to 80.95) 10.11 (1.52 to 67.14)
Marital status
Currently married Ref Ref Ref Ref Ref Ref
Divorced/separated 0.55 (−0.52 to 0.63) 0.22 (−0.36 to 0.81) 0.21 (−0.27 to 0.69) 0.22 (−0.28 to 0.72) 0.82 (0.60 to 1.12) 0.84 (0.61 to 1.15)
Single −0.03 (−1.07 to 1.02) −0.51 (−1.58 to 0.57) −0.31 (−1.18 to 0.55) −0.35 (−1.27 to 0.57) 1.07 (0.56 to 2.05) 0.82 (0.43 to 1.56)
Widowed −0.26 (−1.05 to 0.53) 0.45 (−0.36 to 1.27) −0.02 (−0.68 to 0.63) 0.11 (−0.60 to 0.81) 0.78 (0.52 to 1.17) 0.86 (0.54 to 1.38)
Alcohol consumption
Yes Ref Ref Ref Ref Ref Ref
No −0.23 (−0.73 to 0.28) −0.02 (−0.52 to 0.49) 0.01 (−0.41 to 0.43) 0.10 (0.34 to 0.53) 0.93 (0.71 to 1.22) 0.94 (0.70 to 1.26)
Income per month in USD
<20 Ref Ref Ref Ref Ref Ref
20−60 0.36 (−0.24 to 095) 0.41 (−0.30 to 1.11) −0.22 (−0.72 to 0.27) −0.66 (−1.27 to −0.06) 1.28 (0.93 to 1.77) 1.18 (0.82 to 1.70)
>60 0.79 (0.23 to 1.35) 0.54 (−0.16 to 1.25) −0.06 (−0.53 to 0.40) −0.43 (−1.03 to 0.18) 1.60 (1.18 to 2.17) 1.33 (0.91 to 1.95)
Smoking status
Yes Ref Ref Ref Ref Ref Ref
No 0.64 (−0.48 to 1.75) 0.27 (−0.88 to 1.42) −0.72 (−1.64 to 0.20) −0.87 (−1.85 to 0.12) 2.14 (1.19 to 3.84) 1.62 (0.91 to 2.89)
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Table 6 Comparison of change in CD4 count and QoL among 573 patients not receiving ART at the Mulago HIV clinic in Uganda between April 2012 and December 2013
(Continued)
Depression score No depression
(<16) Ref Ref - - Ref Ref
Probable depression (≥16) −1.07 (−1.46 to −0.67) −1.01 (−1.41 to −0.60) 0.41 (0.33 to 0.52) 0.43 (0.33 to 0.55)
Social support
Yes, family Ref Ref Ref Ref Ref Ref
Yes, other 0.063 (−0.53 to 0.66) 0.003 (−0.60 to 0.60) 0.28 (−0.21 to 0.77) 0.41 (−0.11 to 0.92) 0.91 (0.67 to 1.24) 0.96 (0.69 to 1.33)
None −0.01 (−1.12 to 1.10) −0.01 (−1.10 to 1.07) 0.70 (−0.21 to 1.61) 0.65 (−0.28 to 1.58) 1.10 (0.62 to 1.95) 1.20 (0.65 to 2.20)
Opportunistic infection
Yes Ref Ref Ref Ref Ref Ref
No 0.41 (−0.15 to 0.97) 0.22 (−0.36 to 0.79) 0.59 (0.12 to 1.06) 0.66 (0.17 to 1.16) 1.06 (0.78 to 1.45) 1.02 (0.73 to 1.42)
WHO stage
Stages I and II Ref Ref Ref Ref Ref Ref
Stages III and IV −0.63 (−1.30 to 0.04) −0.51 (−1.19 to 0.17) 0.38 (−0.94 to 0.18) −0.19 (−0.77 to 0.40) 0.86 (0.59 to 1.25) 1.00 (0.68 to 1.45)
Religion
Christian Ref Ref Ref Ref Ref Ref
Muslim −0.74 (−1.39 to −0.09) −0.30 (−0.96 to 0.37) 0.27 (−0.27 to 0.81) 0.24 (−0.33 to 0.82) 1.03 (0.71 to 1.50) 1.19 (0.80to 1.78)
Other −0.55 (−2.42 to 1.31) −0.57 (−2.35 to 1.21) 1.13 (−0.42 to 2.68) 1.40 (−0.13 to 2.94) 1.11 (0.45 to 2.78) 0.82 (0.28 to 2.46)
Employment status
Yes Ref Ref Ref Ref Ref Ref
No −0.28 (−0.87 to 0.31) 0.26 (−0.48 to 1.00) −0.23 (−0.72 to 0.26) −0.39 (−1.02 to 0.25) 0.70 (0.51 to 0.97) 0.73 (0.49 to 1.09)
Abbreviations: 95 % CI, 95 % confidence interval; SE, standard error
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other studies carried out in sub-Saharan Africa [17, 18].
The basic characteristics of our study sample were
similar to the populations in those studies. The major-
ity of participants were females, aged mid-30s with low
educational level, which may be the reason for our
similar results. However, one of the above studies in-
cluded both not on ART and ART-experienced patients
[17] and also was a secondary data analysis of 642 pa-
tients. In the other study, although participants had
CD4 counts lower than 250 cells/μL, they were not on
ART; in addition, it was a cross-sectional study with
only 90 participants [18]. Likewise, another cross-
sectional study in Tanzania reported no association
between change in CD4 count and QoL among 329 pa-
tients who had been on ART for more than 6 months
[20]. The change in CD4 count in that population was
the difference between baseline CD4 count and the
most recent CD4 count. The time between these counts
varied and QoL was measured at one time point. How-
ever, Weinfurt and colleagues found a positive associ-
ation between change in CD4 count and QoL and
reported CD4 count to be a strong long-term predictor
of QoL [16]. That was a double randomized clinical
trial and participants were on ART and followed for a
period of 2 years. In the above study, participants were
aware of their CD4 levels at the time of interview,
which could have influenced their MOS-HIV QoL rat-
ings. They also received ART regimens different to
those of our study group; they received either didano-
sine or didanosine plus delavirdine mesylate. This was
before highly active antiretroviral therapy (HAART)
became available. Besides, it may not be plausible to
compare results from a randomized clinical trial to our
results from a cohort study. Other studies conducted
within the HAART era have also shown some improve-
ments in viral loads and CD4 counts [53, 54]. These
studies did not directly measure the association be-
tween QoL and CD4 counts, and participants had ad-
vanced disease. Call and colleagues also reported CD4
count to be a strong predictor of the following sub-
scales on the SF-36 quality of life measure: physical
component summary, physical functioning, role func-
tion and general health [24]. The 158 participants in
that study were followed for a period of 12 months.
They were enrolled if they were initiating ART or chan-
ging ART regimen. Patients who change ART, most
likely after failing on the first therapy, are more likely
to positively respond with the new therapy both im-
munologically and in terms of improved QoL.
This study has limitations. The 6-month follow-up
for chronic illness may be rather short; a longer follow-
up time is recommended. This was not a randomized
study, and viral load testing could have enriched this
study as a more accurate measure of disease burden.
The large sample size may have caused a weak associ-
ation with GPGI.
Nevertheless, the strengths of this study include the
large sample size and longitudinal design to specifically as-
sess the association between immunological markers and
QoL. To our knowledge this is the first study to look at
this in sub-Saharan Africa. Most importantly, confounders
of QoL were statistically controlled for. The results of the
qualitative sub-study, which provided insight into the con-
text of participants’ lives, help to explain why CD4 count
alone cannot be used to predict QoL.
Conclusions
These data suggest that an increase or decrease in CD4
may not translate to better or worse QoL within a
period of 6 months among PLHIV with relatively high
CD4 count. It may therefore be paramount for clini-
cians and policy makers to consider other factors, such
as income and psychosocial support, in monitoring
QoL among HIV/AIDS patients and not to rely on
change in immunological markers alone. HIV/AIDS is
now an incurable chronic condition; therefore, a good
QoL together with prolonged survival is paramount.
Recommendation
In addition to monitoring immunological markers, other
psychosocial and socioeconomic factors should be under-
scored in management of HIV patients in order to
optimize treatment outcomes.
A similar study with longer follow-up period would
further enrich the findings of this study.
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